(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
Live Chart Being Loaded With Signals
Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland...
Stats | |
---|---|
今日成交量 | 330 887 |
平均成交量 | 336 670 |
市值 | 1.31B |
EPS | $0 ( 2024-05-03 ) |
Last Dividend | $0.100 ( 2012-09-26 ) |
Next Dividend | $0 ( N/A ) |
P/E | -62.49 |
ATR14 | $0.901 (0.75%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-06-13 | Davis Stephen L | Sell | 500 | Common Stock |
2023-06-13 | Hasenmaier Joachim A. | Sell | 2 004 | Common Stock |
2023-06-13 | Eyl Steven M. | Buy | 4 056 | Common Stock |
2023-06-13 | Eyl Steven M. | Buy | 33 111 | Common Stock |
2022-02-28 | Eyl Steven M. | Buy | 20 000 | Non-Qualified Stock Option (right to buy) |
INSIDER POWER |
---|
-9.07 |
Last 100 transactions |
Buy: 575 941 | Sell: 596 011 |
音量 相关性
Heska Corp 相关性 - 货币/商品
Heska Corp 财务报表
Annual | 2022 |
营收: | $257.31M |
毛利润: | $111.17M (43.20 %) |
EPS: | $-1.780 |
FY | 2022 |
营收: | $257.31M |
毛利润: | $111.17M (43.20 %) |
EPS: | $-1.780 |
FY | 2021 |
营收: | $253.74M |
毛利润: | $105.79M (41.69 %) |
EPS: | $-0.110 |
FY | 2020 |
营收: | $197.32M |
毛利润: | $81.29M (41.20 %) |
EPS: | $-1.660 |
Financial Reports:
No articles found.
Heska Corp Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.100 | 2012-03-28 |
Last Dividend | $0.100 | 2012-09-26 |
Next Dividend | $0 | N/A |
Payout Date | 2012-10-10 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | $0.300 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.56 | -- |
Div. Sustainability Score | 3.02 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0.0941 | -- |
Year | Amount | Yield |
---|---|---|
2012 | $0.300 | 4.08% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Royal | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.106 | 1.500 | -2.12 | -3.18 | [0 - 0.5] |
returnOnAssetsTTM | -0.0230 | 1.200 | -0.766 | -0.920 | [0 - 0.3] |
returnOnEquityTTM | -0.0324 | 1.500 | -1.472 | -2.21 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 5.64 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.82 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.96 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.185 | -1.500 | 6.92 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -8.49 | 1.000 | -4.25 | -4.25 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.186 | 2.00 | -0.395 | -0.791 | [0 - 30] |
freeCashFlowPerShareTTM | -1.417 | 2.00 | -0.708 | -1.417 | [0 - 20] |
debtEquityRatioTTM | 0.262 | -1.500 | 8.95 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.429 | 1.000 | 6.18 | 6.18 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.0920 | 1.000 | -3.84 | -3.84 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.113 | 1.000 | -1.737 | -1.737 | [0.2 - 2] |
assetTurnoverTTM | 0.217 | 0.800 | -1.886 | -1.508 | [0.5 - 2] |
Total Score | 3.02 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -91.49 | 1.000 | -9.34 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0324 | 2.50 | -0.946 | -2.21 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.417 | 2.00 | -0.472 | -1.417 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.186 | 2.00 | -0.395 | -0.791 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.830 | 1.500 | -8.87 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.0957 | 1.000 | -4.89 | 0 | [0.1 - 0.5] |
Total Score | -2.83 |
Heska Corp
Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; and turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force, and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was founded in 1988 and is based in Loveland, Colorado.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。